Indian pharma firms may yet survive Trump's 200% tariff bombshell

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited. India's cost advantage, America's dependence on imported generics and lengthy US factory approval timelines could make large-scale manufacturing shifts difficult despite Trump's reshoring push.

Raccontata datimesofindia.indiatimes.comeconomictimes.indiatimes.comfrance24.comhindustantimes.comnewsbytesapp.comthehindubusinessline.comtheprint.inindependent.co.uk